The Themes Hidden in August's Lobbying Data

Section A: The Themes Hidden in August's Lobbying Data

Donor Pressure Spurs Lobbying on Afghan Healthcare Aid

August 2026 saw heightened advocacy efforts as groups like the International Rescue Committee Inc., together with Molnlycke Health Care AB, met with EU officials such as Direct. Gen. International Partnerships and Comm Roswall (Environment) to discuss the continuity of healthcare aid for Afghanistan. This activity aligns with the European Commission’s renewed commitment to humanitarian and medical support in the region, following pronounced reductions in international donor funding.

📎 EEAS briefing — Five years after Kabul takeover: EU support for Afghan people continues · EU Humanitarian Operations Afghanistan

Medical Device Firms Respond to New EU Compliance Demands

As the EU's Medical Devices Regulation nears new implementation deadlines, companies such as Molnlycke Health Care AB are engaging directly with policymakers, including Comm Roswall (Environment), to discuss conformity and certification requirements. This increase in lobbying, which also involves industry groups like MedTech Europe in meetings with Direct. Gen. Trade, follows the European Commission’s regulatory updates, which introduce stricter assessment standards and tighter industry timelines.

📎 Commission announcement · New Medical Device Regulation Guidance

Pharma Groups Press for PFAS Exemptions Amid EU Ban

Pharmaceutical companies, including Pfizer Inc., have stepped up lobbying around the EU’s impending restriction on PFAS chemicals, holding meetings with EVP Sejourne (Industry and SMEs) as draft opinions from ECHA signal sweeping changes for the sector. These efforts come amid ongoing consultations and industry concerns over regulatory impacts and exemption criteria for critical healthcare applications.

📎 ECHAs update on the REACH restriction on PFAS · EU PFAS Restriction Under REACH: What the 2026 ECHA Opinions Mean for ...

Section B: Lobbying Activity by Industry

This section compares, by industry, the lobbying activity with the European Commission last month to its historical average.

Industry Lobbying Activity, August 2026

In August 2026, 3 industries from this sector were active in lobbying meetings with the European Commission, led by Medical and Dental Instruments.

On the quieter side, Pharmaceutical preparations, Other Social Work w/o Accommodation, and Medical and Dental Instruments saw notably less lobbying activity than their historical average.

Section C: Lobbying by Industry for the Past Year

To contextualize Section B, this chart shows the residual trajectory of the same top industries from Section B over the past 12 months — the deviation from what would be expected after accounting for seasonal patterns and the overall trend. Persistent above-zero values indicate sustained over-activity; persistent below-zero values indicate sustained quiet periods.

Sector Residual (August 2026)

This chart shows the 3 industries in this sector with the largest deviations from expected lobbying activity in August 2026. Positive values run above their seasonal trend, negative values below.

Sector saw lobbying notably below expected levels this month.

Section D: Lobbying Activity by Organization

In this section, we see the organizations with the most unusual lobbying behavior last month, defined by either unusually high or unusually low lobbying activity.

Organization Lobbying Activity, August 2026

In August 2026, 4 organizations from this sector took part in 4 lobbying meetings with the European Commission.

On the quieter side, European Federation of Pharmaceutical Industries and Associations, Bayer AG, Merck Sharp & Dohme Europe Belgium SRL, MEDICINES FOR EUROPE, and AstraZeneca PLC saw notably less lobbying activity than usual.

Section E: Lobbying of Government Institutions in the Past Month

Every lobbying meeting takes place with one of two types of European Commission body: a Commissioner's cabinet (political staff) or a Directorate-General (the civil service). This section shows the organisation-to-institution pairings with the most unusual lobbying activity last month, defined by the largest absolute difference between this month's meeting count and the pair's 12-month rolling average.

Lobbying of Commission Institutions, August 2026 vs 12-Month Avg

In August 2026, 4 organisations from this sector met with 4 Commission bodies across 4 meetings — split across 2 Commissioner cabinets and 2 Directorates-General.

Section F: Organization Lobbying by Subject in the Past Month

This section shows the organisation-to-subject pairings with the most unusual lobbying activity last month. Subjects are classified from each meeting's title text into one of 19 EU policy areas. A meeting covering multiple topics counts toward each of them.

Lobbying by Subject, August 2026 vs 12-Month Avg

In August 2026, 4 organisations from this sector lobbied on 3 policy topics across 4 meetings. Meetings may touch multiple topics, so subject totals can exceed total meetings.

On the quieter side, European Federation of Pharmaceutical Industries and Associations on Healthcare, AstraZeneca PLC on Healthcare, MEDICINES FOR EUROPE on Healthcare, Merck Sharp & Dohme Europe Belgium SRL on Healthcare, and Bayer AG on Healthcare saw notably less lobbying activity than their historical average.

Section G: Most-Lobbied Officials

This section lists the most-frequent lobbying touchpoints between this sector's organisations and individual European Commission officials last month, compared to each pairing's average over the past year.

Most-Lobbied Officials, August 2026

In August 2026, 5 European Commission officials took part in 4 meetings with this sector's lobbyists.

The most-frequent meetings this month were International Rescue Committee Inc and Charlotte Adriaen at Direct. Gen. International Partnerships, Molnlycke Health Care AB and Luis Planas Herrera + 1 other at Comm Roswall (Environment), and Pfizer Inc. and Vilija Sysaite at EVP Sejourne (Industry and SMEs).

Most activity came from Cabinet members (3 meetings), followed by Head of Unit (2).